CO2018014167A2 - Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos - Google Patents
Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismosInfo
- Publication number
- CO2018014167A2 CO2018014167A2 CONC2018/0014167A CO2018014167A CO2018014167A2 CO 2018014167 A2 CO2018014167 A2 CO 2018014167A2 CO 2018014167 A CO2018014167 A CO 2018014167A CO 2018014167 A2 CO2018014167 A2 CO 2018014167A2
- Authority
- CO
- Colombia
- Prior art keywords
- fatty acid
- butanediol
- acid esters
- hydroxybutyrate
- methods
- Prior art date
Links
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 title 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 title 1
- 150000002711 medium chain fatty acid esters Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 5
- 229930195729 fatty acid Natural products 0.000 abstract 5
- 239000000194 fatty acid Substances 0.000 abstract 5
- -1 ß-hydroxybutyrate fatty acid esters Chemical class 0.000 abstract 3
- 150000002148 esters Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/045—Organic compounds containing nitrogen as heteroatom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/003—Esters of saturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
- C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
-
- G—PHYSICS
- G02—OPTICS
- G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G02B1/00—Optical elements characterised by the material of which they are made; Optical coatings for optical elements
- G02B1/04—Optical elements characterised by the material of which they are made; Optical coatings for optical elements made of organic materials, e.g. plastics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/54—Proteins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physical Education & Sports Medicine (AREA)
- General Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662346975P | 2016-06-07 | 2016-06-07 | |
| PCT/US2017/035826 WO2017213999A1 (en) | 2016-06-07 | 2017-06-02 | Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2018014167A2 true CO2018014167A2 (es) | 2019-01-18 |
Family
ID=60578899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2018/0014167A CO2018014167A2 (es) | 2016-06-07 | 2018-12-26 | Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10889538B2 (enExample) |
| EP (2) | EP3465335B1 (enExample) |
| JP (3) | JP7058610B2 (enExample) |
| KR (2) | KR102519244B1 (enExample) |
| CN (2) | CN109477993B (enExample) |
| AU (2) | AU2017278099B2 (enExample) |
| CA (1) | CA3026621A1 (enExample) |
| CO (1) | CO2018014167A2 (enExample) |
| IL (2) | IL263561B (enExample) |
| MX (2) | MX2021009806A (enExample) |
| RU (1) | RU2761829C2 (enExample) |
| SG (1) | SG11201810765PA (enExample) |
| WO (1) | WO2017213999A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021009806A (es) | 2016-06-07 | 2022-11-30 | The J David Gladstone Inst | Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos. |
| AU2018304380B2 (en) | 2017-07-21 | 2022-12-15 | Buck Institute For Research On Aging | S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same |
| WO2019147503A1 (en) | 2018-01-25 | 2019-08-01 | Buck Institute For Research On Aging | Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds |
| US20190248733A1 (en) * | 2018-02-14 | 2019-08-15 | Benjamin Bikman | Oral supplements of fatty acid and amino acid ketone esters to improve metabolic, physical and cognitive health |
| WO2020147983A1 (de) * | 2019-01-17 | 2020-07-23 | Ioi Oleo Gmbh | Verfahren zur herstellung von polyolbasierten estern von gegebenenfalls acylierten hydroxycarbonsäuren |
| EP3880644B1 (de) * | 2019-01-17 | 2023-09-06 | KetoLipix Therapeutics GmbH | Verfahren zur herstellung von verkappten 3-hydroxycarbonsäuren sowie deren salzen und estern |
| EP3880642B1 (de) | 2019-01-17 | 2026-01-14 | KetoLipix Therapeutics GmbH | Verfahren zur herstellung von fettalkoholestern von hydroxycarbonsäuren |
| CN110372502A (zh) * | 2019-07-25 | 2019-10-25 | 润泰化学（泰兴）有限公司 | 一种1,3-二醇的双酯化合成方法 |
| GB201918657D0 (en) | 2019-12-17 | 2020-01-29 | Tdeltas Ltd | Compounds for new use |
| ES2980782T3 (es) * | 2020-07-13 | 2024-10-03 | Ketolipix Therapeutics Gmbh | Procedimiento para la preparación de ésteres de poliglicerol de ácidos policarboxílicos esterificados con oxobutanol |
| BR112023000684A2 (pt) * | 2020-07-13 | 2023-01-31 | Ioi Oleo Gmbh | Método para produzir ésteres de oxobutanol de ácidos carboxílicos poliméricos |
| US20240228422A1 (en) * | 2020-07-13 | 2024-07-11 | Ioi Oleo Gmbh | Process for preparing oxobutanol esters of polymeric carboxylic acids |
| CN112341542B (zh) * | 2021-01-08 | 2021-05-14 | 清华大学 | 一种3-羟基丁酰化修饰蛋白质药物及其制备方法和应用 |
| AU2022212793A1 (en) * | 2021-01-26 | 2023-08-10 | Buck Institute For Research On Aging | Use of exogenous ketone esters to induce weight loss in mammals |
| US12059398B2 (en) * | 2022-08-26 | 2024-08-13 | Health Via Modern Nutrition Inc. | Compositions of 1,3-butanediol and beta-hydroxybutyric acid to provide optimal therapeutic ketosis |
| US20250009707A1 (en) | 2023-06-29 | 2025-01-09 | BOPZ Nutrition Ltd. | Methods of inducing ketosis in non-human mammals |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK85610C (da) | 1952-01-08 | 1958-05-27 | Unilever Nv | Fremgangsmåde til udvinding af fedstoffer af vandige sæbeopløsninger. |
| US4756907A (en) | 1978-10-17 | 1988-07-12 | Stolle Research & Development Corp. | Active/passive immunization of the internal female reproductive organs |
| US4263216A (en) * | 1978-10-20 | 1981-04-21 | The Procter & Gamble Company | Diglyceride manufacture |
| IL59407A (en) * | 1979-03-06 | 1983-12-30 | Sanofi Sa | Di-n-propylacetic acid diesters of glycerol,their preparation and pharmaceutical compositions containing them |
| US4436726A (en) | 1980-12-15 | 1984-03-13 | Fujisawa Pharmaceutical Co., Ltd. | N-Acylpeptide compound, processes for the preparation thereof and the pharmaceutical compositions |
| US5126373A (en) | 1987-11-19 | 1992-06-30 | Henri Brunengraber | Composition for parenteral and oral nutrition |
| BE1001209A3 (fr) | 1987-11-19 | 1989-08-22 | Solvay | Compositions pharmaceutiques contenant un derive de l'acide 3-hydroxybutanoique choisi parmi les oligomeres de cet acide et les esters de cet acide ou de ces oligomeres avec du 1,3-butanediol. |
| US5219757A (en) | 1988-04-27 | 1993-06-15 | Daicel Chemical Industries, Ltd. | Production of optically active 1,3-butanediol by asymmetric assimilation or reduction of 4-hydroxy-2-butanone |
| JP2578658B2 (ja) * | 1989-02-21 | 1997-02-05 | チッソ株式会社 | 光学活性化合物及びその製造法 |
| US5008126A (en) | 1989-06-27 | 1991-04-16 | Nabisco Brands, Inc. | Long chain diol diesters as low calorie fat mimetics |
| IT1240760B (it) * | 1990-02-12 | 1993-12-17 | Sigma Tau Ind Farmaceuti | Esteri di acil-l-carnitine con l'acido gamma-idrossibutirrico e composizioni farmaceutiche che li contengono per l'inibizione della degenerazione neuronale e nel trattamento del coma. |
| ATE129147T1 (de) | 1992-01-08 | 1995-11-15 | Nestle Sa | Kosmetische und dermatologische zusammensetzung, die dioldiester enthält. |
| US5536249A (en) | 1994-03-09 | 1996-07-16 | Visionary Medical Products, Inc. | Pen-type injector with a microprocessor and blood characteristic monitor |
| US6146361A (en) | 1996-09-26 | 2000-11-14 | Becton Dickinson And Company | Medication delivery pen having a 31 gauge needle |
| DE19703471A1 (de) * | 1997-01-31 | 1998-08-06 | Beiersdorf Ag | Kosmetische und dermatologische Lichtschutzformulierungen mit einem Gehalt an Triazinderivaten und Butylenglycoldiestern |
| DK1017379T3 (en) * | 1997-03-17 | 2015-02-16 | Btg Int Ltd | Therapeutic compositions comprising ketone compounds and precursors thereof |
| US6323237B1 (en) | 1997-03-17 | 2001-11-27 | Btg International Limited | Therapeutic compositions |
| WO1998051278A2 (en) * | 1997-05-14 | 1998-11-19 | Inex Pharmaceuticals Corporation | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
| US6197327B1 (en) | 1997-06-11 | 2001-03-06 | Umd, Inc. | Device and method for treatment of dysmenorrhea |
| US6221053B1 (en) | 1998-02-20 | 2001-04-24 | Becton, Dickinson And Company | Multi-featured medication delivery pen |
| US6096010A (en) | 1998-02-20 | 2000-08-01 | Becton, Dickinson And Company | Repeat-dose medication delivery pen |
| US6248095B1 (en) | 1998-02-23 | 2001-06-19 | Becton, Dickinson And Company | Low-cost medication delivery pen |
| EP1052240B1 (en) * | 1999-05-11 | 2003-03-19 | Dow AgroSciences LLC | Process for the preparation of substituted 3-hydroxybutyrate esters |
| US6277099B1 (en) | 1999-08-06 | 2001-08-21 | Becton, Dickinson And Company | Medication delivery pen |
| US6476079B1 (en) | 1999-12-23 | 2002-11-05 | Leiras Oy | Devices for the delivery of drugs having antiprogestinic properties |
| US20080009467A1 (en) | 2000-05-01 | 2008-01-10 | Accera, Inc. | Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism |
| AU2002211666A1 (en) * | 2000-10-11 | 2002-04-22 | Esperion Therapeutics, Inc. | Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
| EP1528053A1 (en) | 2003-10-31 | 2005-05-04 | Lonza Ag | Process for the preparation of (S)- or (R)-4-halo-3-hydroxybutyrates |
| JP2006063001A (ja) | 2004-08-25 | 2006-03-09 | Takasago Internatl Corp | 光学活性β−ブチロラクトンの製造方法 |
| CN101326172A (zh) * | 2005-12-07 | 2008-12-17 | 思珀药品有限公司 | 茉莉酮酸酯衍生物、药物组合物及它们的使用方法 |
| US7988883B2 (en) | 2006-02-10 | 2011-08-02 | Dupont Tate & Lyle Bio Products Company, Llc | Heat transfer compositions comprising renewably-based biodegradable 1,3-propanediol |
| WO2008089462A2 (en) * | 2007-01-18 | 2008-07-24 | Evolva Sa | Substituted 1,3-dioxanes and their uses |
| JP5054418B2 (ja) * | 2007-04-23 | 2012-10-24 | ポーラ化成工業株式会社 | クレンジング用の化粧料に好適な皮膚外用剤 |
| CN102164884B (zh) | 2008-08-21 | 2015-03-11 | 伊希斯创新有限公司 | 羟基丁酸酯及其医学用途 |
| US8642654B2 (en) | 2009-04-16 | 2014-02-04 | Isis Innovation Limited | Hydroxybutyrate ester and medical use thereof |
| US9034613B2 (en) | 2009-04-16 | 2015-05-19 | Isis Innovation Limited | Process for the preparation of (3R)-hydroxybutyl (3R)-hydroxybutyrate by enzymatic enantioselective reduction employing Lactobacillus brevis alcohol dehydrogenase |
| GB201002983D0 (en) | 2010-02-22 | 2010-04-07 | Tdeltas Ltd | Nutritinal composition |
| US9868837B2 (en) * | 2010-04-28 | 2018-01-16 | Arkema Inc. | Method of improving stability of polyurethane polyol blends containing halogenated olefin blowing agent |
| KR101243240B1 (ko) * | 2010-07-19 | 2013-04-04 | (주)에이씨티 | 신규 알킬디올 유도체화합물 및 이를 포함하는 미백용 피부외용제조성물 |
| CN103360243B (zh) * | 2012-03-31 | 2015-06-17 | 中国石油化工股份有限公司 | 一种1,3-二酰氧基丙烷类化合物的制备方法 |
| CN104272147B (zh) * | 2012-05-01 | 2015-10-21 | 柯尼卡美能达株式会社 | 相位差膜、偏振片的制造方法及液晶显示装置 |
| SG11201507685UA (en) | 2013-03-14 | 2015-10-29 | Isis Innovation | Process for producing (r)-3-hydroxybutyl (r)-3-hydroxybutyrate |
| MY180761A (en) | 2013-03-19 | 2020-12-08 | Univ South Florida | Compositions and methods for producing elevated and sustained ketosis |
| US11814664B2 (en) | 2013-05-24 | 2023-11-14 | Genomatica, Inc. | Microorganisms and methods for producing (3R)-hydroxybutyl (3R)-hydroxybutyrate |
| AU2014306149B2 (en) * | 2013-08-06 | 2019-09-19 | Imago Biosciences Inc. | KDM1A inhibitors for the treatment of disease |
| WO2016123229A1 (en) | 2015-01-29 | 2016-08-04 | Yale University | Compositions and methods for treating nlrp3 inflammasome-related diseases and disorders |
| US20180200220A1 (en) | 2015-07-10 | 2018-07-19 | Cognate Nutritionals, Inc. | Prophylaxis and mitigation of migraine headaches using ketogenic medium chain triglycerides, ketone esters, and other ketogenic sources |
| US10245242B1 (en) | 2017-11-22 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| MX2021009806A (es) | 2016-06-07 | 2022-11-30 | The J David Gladstone Inst | Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos. |
| AU2018304380B2 (en) | 2017-07-21 | 2022-12-15 | Buck Institute For Research On Aging | S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same |
| WO2019147503A1 (en) | 2018-01-25 | 2019-08-01 | Buck Institute For Research On Aging | Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds |
| US20190262415A1 (en) | 2018-02-26 | 2019-08-29 | Ketologie LLC | Supplement for inducing and sustaining nutritional ketosis |
-
2017
- 2017-06-02 MX MX2021009806A patent/MX2021009806A/es unknown
- 2017-06-02 WO PCT/US2017/035826 patent/WO2017213999A1/en not_active Ceased
- 2017-06-02 KR KR1020197000530A patent/KR102519244B1/ko active Active
- 2017-06-02 JP JP2018564979A patent/JP7058610B2/ja active Active
- 2017-06-02 EP EP17810768.6A patent/EP3465335B1/en active Active
- 2017-06-02 MX MX2018015302A patent/MX385367B/es unknown
- 2017-06-02 CN CN201780041428.2A patent/CN109477993B/zh active Active
- 2017-06-02 CA CA3026621A patent/CA3026621A1/en active Pending
- 2017-06-02 KR KR1020227044586A patent/KR102638807B1/ko active Active
- 2017-06-02 EP EP25179114.1A patent/EP4585270A3/en active Pending
- 2017-06-02 RU RU2018143895A patent/RU2761829C2/ru active
- 2017-06-02 SG SG11201810765PA patent/SG11201810765PA/en unknown
- 2017-06-02 AU AU2017278099A patent/AU2017278099B2/en active Active
- 2017-06-02 US US16/306,524 patent/US10889538B2/en active Active
- 2017-06-02 CN CN202111675586.8A patent/CN114292190B/zh active Active
-
2018
- 2018-12-06 IL IL263561A patent/IL263561B/en unknown
- 2018-12-26 CO CONC2018/0014167A patent/CO2018014167A2/es unknown
-
2019
- 2019-07-29 US US16/525,437 patent/US10562839B2/en active Active
- 2019-07-31 US US16/528,524 patent/US10647658B2/en active Active
-
2020
- 2020-12-02 US US17/110,236 patent/US11608308B2/en active Active
-
2021
- 2021-06-07 AU AU2021203726A patent/AU2021203726C1/en active Active
- 2021-10-26 JP JP2021174538A patent/JP7479337B2/ja active Active
-
2022
- 2022-03-24 IL IL291694A patent/IL291694A/en unknown
-
2023
- 2023-12-21 JP JP2023215845A patent/JP2024028287A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018015302A (es) | Esteres de acidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y metodos para usar los mismos. | |
| CO2018000344A2 (es) | Derivados de piperidina 1,4-sustituidos | |
| CL2019001711A1 (es) | Composiciones y métodos para inhibir la acción de la arginasa. | |
| DOP2017000151A (es) | Derivados de quinazolina utilizados para tratar el vih | |
| UY34888A (es) | Inhibidores del virus de la hepatitis c | |
| UY36391A (es) | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen | |
| MX2019009695A (es) | Inhibidores espirociclicos de catepsina c. | |
| DK3330259T3 (da) | 1,3,4-oxadiazolamidderivativ-forbindelse som histondeacetylase-6-inhibitor og farmaceutisk sammensætning indeholdende denne | |
| UY36151A (es) | ?una composición farmacéutica que comprende un inhibidor de fosfoinosítido 3-quinasa delta y un corticosteroide?. | |
| DOP2012000257A (es) | Derivados del acido 1-amino-2-ciclopropiletilboronico | |
| DOP2018000058A (es) | Inhibidores de ezh2 | |
| MX2017016370A (es) | Derivados de 4-bencil y 4-benzoil piperidina sustituidos. | |
| BR112016022593A2 (pt) | composições e métodos para modular a expressão do fator b do complemento | |
| CO2018005315A2 (es) | Moduladores de la interacción de sestrina-gator2 y sus usos | |
| MX2019001011A (es) | Compuestos farmaceuticos. | |
| MX2018003592A (es) | Sales y formas solidas de un antibiotico de monobactam. | |
| CL2015002608A1 (es) | Compuesto de amino-pirazol y usos medicinales relacionados. | |
| BR112013020975A2 (pt) | compostos contendo fósforo como inibidores de proteína quinases | |
| MX2017005646A (es) | Agentes inmunorreguladores. | |
| CO7131360A2 (es) | Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa | |
| SV2018005621A (es) | Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h | |
| DOP2018000062A (es) | Piridinona dicaboxamidas para uso como inhibidores de bromodominio | |
| BR112017003745A2 (pt) | inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico | |
| MX2017011500A (es) | Combinaciones y formulaciones de dosis fijas que comprenden ácido 8-hidroxi-2,2,14,14- tetrametilpentadecanodioico (etc1002) y una o más estatinas y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
| MX2019006920A (es) | Derivados de la espiropiperidina. |